Bioliberty
The Bank has committed £3m to Bioliberty, which emerged from the University of Edinburgh and develops technology that supports physical rehabilitation for the increasing number of people recovering from mobility-limiting conditions or injuries.
The platform combines AI with soft‑robotic wearable devices to help therapists deliver higher‑intensity therapy while capturing clear, objective data on patient recovery. This approach makes therapy more efficient, helps accelerate progress, and gives clinical teams the visibility they need to make more informed decisions and coordinate care more effectively.
Read our news release here
About Bioliberty
Bioliberty is an Edinburgh- and Boston-based startup on a mission to give everyone the best chance at recovery from a mobility-limiting condition or injury, empowering individuals to reclaim their independence.
The company develops technology that delivers therapy and analyses functional movement data to inform recovery progress and support discharge planning.
Bioliberty holds eight patents across its core technologies, Lifehub and Lifeglov — both of which are FDA-registered.
Why we invested
The funding will support continued product development and manufacturing in Scotland and will enable further commercial expansion in the United States, where the company’s technology is already used in several leading rehabilitation facilities.
“Our investment in this IP-rich company aligns to our innovation mission, helping Bioliberty to scale its technology internationally and further strengthen its home-grown excellence in robotics and AI. Critically, their products and solutions deliver tangible benefits to patients.
“We are pleased to help them scale their rollout and to help solidify Scotland’s healthtech and AI expertise, building on our recognised engineering heritage and research excellence.”
Key Information
Key Quote
Rowan Armstrong, co‑founder and chief executive officer of Bioliberty, said: “This investment allows us to significantly expand our capabilities, from advancing how we measure patient recovery using computer vision and AI‑driven assessments, to extending our product into patients’ homes.
“Scotland has provided a strong foundation for Bioliberty, offering access to world‑class engineering talent and a highly collaborative research environment. This funding will enable us to grow our team in Scotland, create high‑value jobs, and continue building technology here that supports better rehabilitation outcomes.”
Alignment to the United Nation's Sustainable Development Goals
Good Health and Well-being
Decent Work and Economic Growth
